Related Experiment Video
Updated: Jul 29, 2026
10:00
High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis
U Sriram1, L F Barcellos, P Villoslada
1Department of Neurology, University of California, San Francisco 94143-0435, USA.
Genes and Immunity
|March 6, 2003
Summary
This study investigated genetic variations in interferon receptor genes for multiple sclerosis (MS) patients treated with interferon beta (IFNbeta). No significant associations were found, though one polymorphism showed a potential trend needing further research.
Area of Science:
- Neuroimmunology
- Pharmacogenomics
Background:
- Multiple sclerosis (MS) is a chronic central nervous system inflammatory disease with significant disability.
- Interferon beta (IFNbeta) therapy offers partial benefits, but many patients are non-responders.
Purpose of the Study:
- To explore the pharmacogenomic impact of interferon receptor gene polymorphisms (IFNAR1, IFNAR2) on IFNbeta treatment response in MS patients.
- To assess the association of these polymorphisms with MS susceptibility.
Main Methods:
- Analyzed eight polymorphisms in IFNAR1 and IFNAR2 genes in 147 MS patients receiving IFNbeta.
- Classified patients as responders or non-responders based on clinical endpoints.
- Conducted family-based association analysis for MS susceptibility.
Main Results:
- No significant differences in treatment response or non-response were linked to the studied IFNAR gene polymorphisms.
- A single nucleotide polymorphism (SNP 16469) in IFNAR1 showed a trend towards association with relapse-free status, requiring further validation.
- No significant association was found between IFNAR gene polymorphisms and MS susceptibility.
Conclusions:
- IFNAR1 and IFNAR2 gene polymorphisms do not appear to be major determinants of IFNbeta treatment response in MS.
- Further investigation is needed to confirm the potential role of SNP 16469 in predicting relapse-free status.
- These polymorphisms are not significantly associated with susceptibility to developing MS.
More Related Videos
Related Concept Videos
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...